1
|
Florax AA, Doeleman MJH, de Roock S, van der Linden N, Schatorjé E, Currie G, Marshall DA, IJzerman MJ, Yeung RSM, Benseler SM, Vastert SJ, Wulffraat NM, Swart JF, Kip MMA. Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing tumour necrosis factor-alfa inhibitors in juvenile idiopathic arthritis. Rheumatology (Oxford) 2023:kead688. [PMID: 38123516 DOI: 10.1093/rheumatology/kead688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 09/27/2023] [Accepted: 10/27/2023] [Indexed: 12/23/2023] Open
Abstract
OBJECTIVE To quantify differences in hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNFi in JIA patients. METHODS Retrospective analysis of prospectively collected data from electronic medical records of paediatric JIA patients treated with TNFi, which were either immediately discontinued, spaced (increased treatment interval) or tapered (reduced subsequent doses). Costs of hospital-associated resource use (consultations, medication, radiology procedures, laboratory testing, procedures under general anaesthesia, hospitalisation) and associated travel costs and productivity losses were quantified during clinically inactive disease until TNFi withdrawal (pre-withdrawal period) and compared with costs during the first and second year after withdrawal initiation (first and second year post-withdrawal). RESULTS Fifty-six patients were included of whom 26 immediately discontinued TNFi, 30 spaced and zero tapered. Mean annual costs were €9,165/patient on active treatment (pre-withdrawal) and decreased significantly to €5,063/patient (-44.8%) and €6,569/patient (-28.3%) in the first and second year post-withdrawal, respectively (p< 0.05). Of these total annual costs, travel costs plus productivity losses were €834/patient, €1,180/patient, and €1,320/patient, in the three periods respectively. Medication comprised 80.7%, 61.5% and 72.4% of total annual costs in the pre-withdrawal, first, and second year post-withdrawal period, respectively. CONCLUSION In the first two years after initiating withdrawal, the total annual costs are decreased compared with the pre-withdrawal period. However, cost reductions were lower in the second year compared with the first year post-withdrawal, primarily due to restarting or intensifying biologics. To support biologic withdraw decisions, future research should assess the full long-term societal cost impacts, and include all biologics.
Collapse
Affiliation(s)
- Anna A Florax
- Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - Martijn J H Doeleman
- Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
| | - Sytze de Roock
- Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
| | - Naomi van der Linden
- Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - Ellen Schatorjé
- Department of Paediatric Rheumatology, St Maartenskliniek, Nijmegen, The Netherlands
- Department of Paediatric Rheumatology and Immunology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Gillian Currie
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada
- Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Deborah A Marshall
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada
- Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Maarten J IJzerman
- Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - Rae S M Yeung
- Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, Immunology and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| | - Susanne M Benseler
- Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada
- Division of Rheumatology, Department of Pediatrics, Alberta Children's Hospital, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Sebastiaan J Vastert
- Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
- European Reference Network RITA (rare immunodeficiency autoinflammatory and autoimmune diseases network)
| | - Nico M Wulffraat
- Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
- European Reference Network RITA (rare immunodeficiency autoinflammatory and autoimmune diseases network)
| | - Joost F Swart
- Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands
- Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
- European Reference Network RITA (rare immunodeficiency autoinflammatory and autoimmune diseases network)
| | - Michelle M A Kip
- Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands
- Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands
| |
Collapse
|
2
|
Gieling J, van den Bemt B, Hoppenreijs E, Schatorjé E. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors. Pediatr Rheumatol Online J 2022; 20:109. [PMID: 36471348 PMCID: PMC9721079 DOI: 10.1186/s12969-022-00769-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Accepted: 11/08/2022] [Indexed: 12/07/2022] Open
Abstract
BACKGROUND Biologic disease-modifying antirheumatic drugs (bDMARDs) have changed the treatment of juvenile idiopathic arthritis (JIA) patients notably, as bDMARDs enable substantially more patients to achieve remission. When sustained remission is achieved, tapering or even discontinuation of the bDMARD is advocated, to reduce side effects and costs. However, when and how to discontinue bDMARD therapy and what happens afterwards, is less known. OBJECTIVES With this scoping review we aim to collect available data in current literature on relapse rate, time to relapse (TTR) and possible flare associated variables (such as time spent in remission and method of discontinuation) after discontinuing bDMARDs in non-systemic JIA patients. METHODS We performed a literature search until July 2022 using the Pubmed database. All original studies reporting on bDMARD discontinuation in non-systemic JIA patients were eligible. Data on patient- and study characteristics, the applied discontinuation strategy, relapse rates and time to relapse were extracted in a standardized template. RESULTS Of the 680 records screened, 28 articles were included in this review with 456 non-systemic JIA patients who tapered and/or stopped bDMARD therapy. Relapse rate after discontinuation of bDMARDs, either abruptly or following tapering, were 40-48%, 36.8-45.0% and 60-78% at 6, 8 and 12 months respectively. Total relapse rate ranged from 26.3% to 100%, with mean time to relapse (TTR) of 2 to 8.4 months, median TTR 3 to 10 months. All studies stated a good response after restart of therapy after flare. JIA subtype, type of bDMARD, concomitant methotrexate use, treatment duration, tapering method, age, sex, and time in remission could not conclusively be related to relapse rate or TTR. However, some studies reported a positive correlation between flare and antinuclear antibodies positivity, younger age at disease onset, male sex, disease duration and delayed remission, which were not confirmed in other studies. CONCLUSION Flares seem to be common after bDMARD discontinuation, but little is known about which factors influence these flares in JIA patients. Follow up after discontinuation with careful registration of patient variables, information about tapering methods and flare rates are required to better guide tapering and/or stopping of bDMARDs in JIA patients in the future.
Collapse
Affiliation(s)
- Job Gieling
- Department of Pediatric Rheumatology, Pediatrics, Radboud University Medical Center, Nijmegen, the Netherlands.
| | - Bart van den Bemt
- grid.10417.330000 0004 0444 9382Departments of Pharmacy, Sint Maartenskliniek / Radboud University Medical Center, Nijmegen, the Netherlands
| | - Esther Hoppenreijs
- grid.10417.330000 0004 0444 9382Department of Pediatric Rheumatology, Pediatrics, Sint Maartenskliniek / Radboud University Medical Center, Nijmegen, the Netherlands
| | - Ellen Schatorjé
- grid.10417.330000 0004 0444 9382Department of Pediatric Rheumatology, Pediatrics, Sint Maartenskliniek / Radboud University Medical Center, Nijmegen, the Netherlands
| |
Collapse
|
3
|
Wahadat MJ, Van Helden-Meeuwsen CG, Van Tilburg S, Schatorjé E, Hoppenreijs E, Hissink Muller PCE, Van den Berg JM, Schonenberg-Meinema D, Kamphuis S, Versnel M. POS0178 GENE SIGNATURE FINGERPRINTS DIVIDE SLE PATIENTS IN SUBGROUPS WITH COMPARABLE BIOLOGICAL DISEASE PROFILES: A MULTICENTRE LONGITUDINAL STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.4011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Even in the hands of experienced clinicians, clinical phenotyping and predicting treatment responses in Systemic Lupus Erythematosus (SLE) patients remains challenging. Therefore, the identification of biomarkers that can help physicians to divide patients into subgroups based upon aberrantly activated pathways is relevant and might guide future treatment strategies. Extensive blood transcriptional profiling has identified various gene modules that seem promising for stratification of SLE patients into subgroups (1). However, the feasibility to implement these complicated and expensive tests for use in the daily practice of routine clinical laboratories is challenging if not impossible.Objectives:The aim of this study was to develop gene signatures that stratify patients into groups with comparable disease profiles and are feasible to perform in routine clinical laboratories.Methods:To identify coordinated expression of a set of genes and reduce data complexity, genes from 4 previously described modules (Interferon M1.2, Interferon M5.12, Neutrophil- and Plasmablast (PB)(1)) were measured using real-time quantitative PCR expression on whole blood RNA samples. Subsequently, a principle component analysis was used to select 2-5 indicator genes, that represent a specific signature. Expression levels of these genes were measured in healthy donors (n=42) and samples from two independent childhood-onset SLE cohorts (n=51 and n=20). Scores higher than the mean + 2 S.D. score of healthy controls were defined as high gene signature scores. Based on their expression levels, gene signatures were divided over 14 clusters. Associated clusters were subsequently grouped into three gene fingerprints termed 1) all-signatures-low, 2) only high IFN (M1.2 and/or M5.12) and 3) high PB and/or Neutrophil. Disease activity was measured by the SELENA-SLEDAI score.Results:All four gene signatures were higher expressed in patients compared to healthy controls and showed a significant correlation with the SLEDAI. The PB signature showed the highest association with disease activity (r= 0.6512, P<0.0001). In longitudinally collected samples, the PB signature was reduced in patients who were on treatment and showed a significant trend with the SLEDAI. When patients were divided into the described gene fingerprints, the highest SLEDAI scores (median score=8) were observed in the high PB-Neutrophil group. The lowest disease activity (median score =2) was observed in the all-signatures-low group. The same distribution was seen when samples from a second time point were divided based on this stratification method and this was also reproduced in samples from an independent SLE cohort (figure 1).Conclusion:Various gene signatures are associated with disease activity, which underlines the involvement of different pathophysiological mechanisms in SLE. Combining these signatures into gene fingerprints can help to stratify patients into comparable groups and guide individualized treatment choices for patients in the future.References:[1]Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016;165(6):1548-50.Figure 1.SELENA-SLEDAI scores based on gene fingerprint distribution. Blue indicates time point one of cohort 1 (n=51); pink indicates time point two of cohort 1 (n=45); red indicates time point one of the replication cohort (n=20)Disclosure of Interests:None declared
Collapse
|
4
|
Verwoerd A, Armbrust W, Cowan K, van den Berg L, de Boer J, Bookelman S, Britstra M, Cappon J, Certan M, Dedding C, van den Haspel K, Muller PH, Jongsma K, Lelieveld O, van Loosdregt J, Olsder W, Rocha J, Schatorjé E, Schouten N, Swart JF, Vastert S, Walter M, Schoemaker CG. Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2021; 19:52. [PMID: 33827608 PMCID: PMC8028801 DOI: 10.1186/s12969-021-00540-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 03/23/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Involving the end-users of scientific research (patients, carers and clinicians) in setting research priorities is important to formulate research questions that truly make a difference and are in tune with the needs of patients. We therefore aimed to generate a national research agenda for Juvenile Idiopathic Arthritis (JIA) together with patients, their caregivers and healthcare professionals through conducting a nationwide survey among these stakeholders. METHODS The James Lind Alliance method was used, tailored with additional focus groups held to involve younger patients. First, research questions were gathered through an online and hardcopy survey. The received questions that were in scope were summarised and a literature search was performed to verify that questions were unanswered. Questions were ranked in the interim survey, and the final top 10 was chosen during a prioritisation workshop. RESULTS Two hundred and seventy-eight respondents submitted 604 questions, of which 519 were in scope. Of these 604 questions, 81 were generated in the focus groups with younger children. The questions were summarised into 53 summary questions. An evidence checking process verified that all questions were unanswered. A total of 303 respondents prioritised the questions in the interim survey. Focus groups with children generated a top 5 of their most important questions. Combining this top 5 with the top 10s of patients, carers, and clinicians led to a top 21. Out of these, the top 10 research priorities were chosen during a final workshop. Research into pain and fatigue, personalised treatment strategies and aetiology were ranked high in the Top 10. CONCLUSIONS Through this study, the top 10 research priorities for JIA of patients, their caregivers and clinicians were identified to inform researchers and research funders of the research topics that matter most to them. The top priority involves the treatment and mechanisms behind persisting pain and fatigue when the disease is in remission.
Collapse
Affiliation(s)
- Anouk Verwoerd
- grid.7692.a0000000090126352Centre for Translational Immunology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands ,grid.417100.30000 0004 0620 3132Department of Paediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, Lundlaan 6, 3584 EA Utrecht, The Netherlands
| | - Wineke Armbrust
- grid.4494.d0000 0000 9558 4598University of Groningen, University Medical Centre Groningen, Department of Paediatric Rheumatology and Immunology, Beatrix Children’s Hospital, Hanzeplein 1, 9713 GZ Groningen, The Netherlands ,Dutch Society for Paediatric Rheumatology (NVKR), Mercatorlaan 1200, 3528 BL Utrecht, The Netherlands
| | - Katherine Cowan
- grid.5491.90000 0004 1936 9297James Lind Alliance, National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre (NETSCC), based at the University of Southampton, Alpha House, Enterprise Road, Southampton, SO16 7NS UK
| | - Lotte van den Berg
- Dutch JIA Patient and Parent Organisation (JVN), member of ENCA, Pius X-straat 49, 5121 EP Rijen, The Netherlands
| | - Joke de Boer
- grid.7692.a0000000090126352Department of Ophthalmology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
| | - Sanne Bookelman
- Dutch JIA Patient and Parent Organisation (JVN), member of ENCA, Pius X-straat 49, 5121 EP Rijen, The Netherlands
| | - Marjan Britstra
- Dutch JIA Patient and Parent Organisation (JVN), member of ENCA, Pius X-straat 49, 5121 EP Rijen, The Netherlands
| | - Jeannette Cappon
- grid.418029.60000 0004 0624 3484Reade, Centre for Rehabilitation and Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands ,Dutch Health Professionals in Paediatric Rheumatology (NHPKR), Amsterdam, The Netherlands
| | - Maria Certan
- grid.417100.30000 0004 0620 3132Department of Paediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, Lundlaan 6, 3584 EA Utrecht, The Netherlands ,grid.5477.10000000120346234Department of Science, University College Roosevelt, Lange Noordstraat 1, 4331 CB Middelburg, The Netherlands
| | - Christine Dedding
- Department of Medical Humanities, Amsterdam University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| | - Karin van den Haspel
- Dutch JIA Patient and Parent Organisation (JVN), member of ENCA, Pius X-straat 49, 5121 EP Rijen, The Netherlands
| | - Petra Hissink Muller
- Dutch Society for Paediatric Rheumatology (NVKR), Mercatorlaan 1200, 3528 BL Utrecht, The Netherlands ,Department of Paediatric Immunology and Rheumatology, Willem-Alexander Children’s Hospital, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
| | - Karin Jongsma
- grid.7692.a0000000090126352Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
| | - Otto Lelieveld
- Dutch Health Professionals in Paediatric Rheumatology (NHPKR), Amsterdam, The Netherlands ,University of Groningen, University Medical Centre Groningen, Department of Rehabilitation Medicine, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Jorg van Loosdregt
- grid.7692.a0000000090126352Centre for Translational Immunology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands ,grid.417100.30000 0004 0620 3132Department of Paediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, Lundlaan 6, 3584 EA Utrecht, The Netherlands
| | - Wendy Olsder
- Youth-R-Well.com, Patient Organisation for Young Patients, member of EULAR PARE, Eikstraat 3, 3434 TD Nieuwegein, The Netherlands
| | - Johanna Rocha
- Youth-R-Well.com, Patient Organisation for Young Patients, member of EULAR PARE, Eikstraat 3, 3434 TD Nieuwegein, The Netherlands
| | - Ellen Schatorjé
- Dutch Society for Paediatric Rheumatology (NVKR), Mercatorlaan 1200, 3528 BL Utrecht, The Netherlands ,grid.461578.9Department of Paediatric Immunology and Rheumatology, Amalia Children’s Hospital, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands ,Department of Paediatric Rheumatology, St. Maartenskliniek, Dokter Kopstraat 1, 5835 DV Beugen, The Netherlands
| | - Natasja Schouten
- Dutch JIA Patient and Parent Organisation (JVN), member of ENCA, Pius X-straat 49, 5121 EP Rijen, The Netherlands
| | - Joost F. Swart
- grid.417100.30000 0004 0620 3132Department of Paediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, Lundlaan 6, 3584 EA Utrecht, The Netherlands ,Dutch Society for Paediatric Rheumatology (NVKR), Mercatorlaan 1200, 3528 BL Utrecht, The Netherlands
| | - Sebastiaan Vastert
- grid.7692.a0000000090126352Centre for Translational Immunology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands ,grid.417100.30000 0004 0620 3132Department of Paediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, Lundlaan 6, 3584 EA Utrecht, The Netherlands ,Dutch Society for Paediatric Rheumatology (NVKR), Mercatorlaan 1200, 3528 BL Utrecht, The Netherlands
| | - Margot Walter
- Dutch Health Professionals in Paediatric Rheumatology (NHPKR), Amsterdam, The Netherlands ,grid.5645.2000000040459992XDepartment of Rheumatology, Erasmus University Medical Centre, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
| | - Casper G. Schoemaker
- grid.417100.30000 0004 0620 3132Department of Paediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, Lundlaan 6, 3584 EA Utrecht, The Netherlands ,Dutch JIA Patient and Parent Organisation (JVN), member of ENCA, Pius X-straat 49, 5121 EP Rijen, The Netherlands ,grid.5477.10000000120346234Faculty of Medicine, Utrecht University, Universiteitsweg 98, 3584 CG Utrecht, The Netherlands
| |
Collapse
|
5
|
Schoemaker CG, Armbrust W, Swart JF, Vastert SJ, van Loosdregt J, Verwoerd A, Whiting C, Cowan K, Olsder W, Versluis E, van Vliet R, Fernhout MJ, Bookelman SL, Cappon J, van den Berg JM, Schatorjé E, Muller PCEH, Kamphuis S, de Boer J, Lelieveld OTHM, van der Net J, Jongsma KR, van Rensen A, Dedding C, Wulffraat NM. Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol. Pediatr Rheumatol Online J 2018; 16:57. [PMID: 30219072 PMCID: PMC6139167 DOI: 10.1186/s12969-018-0276-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Accepted: 09/10/2018] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND Research on Juvenile Idiopathic Arthritis (JIA) should support patients, caregivers/parents (carers) and clinicians to make important decisions in the consulting room and eventually to improve the lives of patients with JIA. Thus far these end-users of JIA-research have rarely been involved in the prioritisation of future research. MAIN BODY Dutch organisations of patients, carers and clinicians will collaboratively develop a research agenda for JIA, following the James Lind Alliance (JLA) methodology. In a 'Priority Setting Partnership' (PSP), they will gradually establish a top 10 list of the most important unanswered research questions for JIA. In this process the input from clinicians, patients and their carers will be equally valued. Additionally, focus groups will be organised to involve young people with JIA. The involvement of all contributors will be monitored and evaluated. In this manner, the project will contribute to the growing body of literature on how to involve young people in agenda setting in a meaningful way. CONCLUSION A JIA research agenda established through the JLA method and thus co-created by patients, carers and clinicians will inform researchers and research funders about the most important research questions for JIA. This will lead to research that really matters.
Collapse
Affiliation(s)
- Casper G. Schoemaker
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,Netherlands JIA Patient and Parent Organisation, member of ENCA, Amsterdam, The Netherlands ,0000 0001 2208 0118grid.31147.30National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands ,0000 0004 0620 3132grid.417100.3Department of Paediatric Rheumatology, University Medical Centre Utrecht, Wilhelmina Children’s Hospital, Room KC.03.063.0, P.O. box 85090, 3508 AB Utrecht, The Netherlands
| | - Wineke Armbrust
- 0000 0004 0407 1981grid.4830.fUniversity Medical Center Groningen (UMCG), Beatrix Childrens Hospital, Dept Pediatric Rheumatology and Immunology, University of Groningen, Groningen, The Netherlands ,Dutch Association for Pediatric Rheumatology, Amsterdam, The Netherlands
| | - Joost F. Swart
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,Dutch Association for Pediatric Rheumatology, Amsterdam, The Netherlands ,0000000120346234grid.5477.1Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
| | - Sebastiaan J. Vastert
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,0000000120346234grid.5477.1Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
| | - Jorg van Loosdregt
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,0000000120346234grid.5477.1Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
| | - Anouk Verwoerd
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,0000000120346234grid.5477.1Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
| | - Caroline Whiting
- 0000 0004 1936 9297grid.5491.9James Lind Alliance, National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre (NETSCC), based at the University of Southampton, Southampton, UK
| | - Katherine Cowan
- 0000 0004 1936 9297grid.5491.9James Lind Alliance, National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre (NETSCC), based at the University of Southampton, Southampton, UK
| | - Wendy Olsder
- Youth-R-Well.com, Young Patient Organisation, The Netherlands, member of EULAR PARE, Amsterdam, The Netherlands
| | - Els Versluis
- Netherlands JIA Patient and Parent Organisation, member of ENCA, Amsterdam, The Netherlands
| | - Rens van Vliet
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,Netherlands JIA Patient and Parent Organisation, member of ENCA, Amsterdam, The Netherlands
| | - Marlous J. Fernhout
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,Netherlands JIA Patient and Parent Organisation, member of ENCA, Amsterdam, The Netherlands
| | - Sanne L. Bookelman
- Netherlands JIA Patient and Parent Organisation, member of ENCA, Amsterdam, The Netherlands
| | - Jeannette Cappon
- 0000 0004 0624 3484grid.418029.6Reade, Centre for Rehabilitation and Rheumatology, Department Rehabilitation, Amsterdam, The Netherlands ,Dutch Health Professionals in Pediatric Rheumatology (DHPPR), Amsterdam, The Netherlands
| | - J. Merlijn van den Berg
- Dutch Association for Pediatric Rheumatology, Amsterdam, The Netherlands ,0000 0004 0435 165Xgrid.16872.3aPaediatric rheumatology, Emma Children’s Hospital, University Medical Centre Amsterdam, Amsterdam, The Netherlands
| | - Ellen Schatorjé
- Dutch Association for Pediatric Rheumatology, Amsterdam, The Netherlands ,grid.461578.9Paediatric Rheumatology, Amalia Children’s Hospital, Radboudumc, Nijmegen, The Netherlands ,Paediatric Rheumatology, St. Maartenskliniek, Nijmegen, The Netherlands
| | - Petra C. E. Hissink Muller
- Dutch Association for Pediatric Rheumatology, Amsterdam, The Netherlands ,0000000089452978grid.10419.3dPaediatric Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands ,000000040459992Xgrid.5645.2Paediatric Rheumatology, Sophia Children’s Hospital, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Sylvia Kamphuis
- Dutch Association for Pediatric Rheumatology, Amsterdam, The Netherlands ,000000040459992Xgrid.5645.2Paediatric Rheumatology, Sophia Children’s Hospital, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Joke de Boer
- 0000000120346234grid.5477.1Faculty of Medicine, Utrecht University, Utrecht, The Netherlands ,0000000090126352grid.7692.aDepartment of Ophthalmology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Otto T. H. M. Lelieveld
- Dutch Health Professionals in Pediatric Rheumatology (DHPPR), Amsterdam, The Netherlands ,0000 0004 0407 1981grid.4830.fUniversity Medical Center Groningen, Center for Rehabilitation, University of Groningen, Groningen, The Netherlands
| | - Janjaap van der Net
- 0000000120346234grid.5477.1Faculty of Medicine, Utrecht University, Utrecht, The Netherlands ,Dutch Health Professionals in Pediatric Rheumatology (DHPPR), Amsterdam, The Netherlands ,0000000090126352grid.7692.aChild Development and Exercise Center, Division of Pediatrics. Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Karin R. Jongsma
- 0000000090126352grid.7692.aJulius Center for Health Sciences and Primary Care Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Annemiek van Rensen
- PGOsupport, Dutch Networking Organisation for Patient Organisations, Utrecht, The Netherlands
| | - Christine Dedding
- Department of Medical Humanities, Amsterdam UMC, Amsterdam, The Netherlands
| | - Nico M. Wulffraat
- 0000000090126352grid.7692.aPediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands ,0000000120346234grid.5477.1Faculty of Medicine, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
6
|
Schatorjé E, van der Flier M, Seppänen M, Browning M, Morsheimer M, Henriet S, Neves JF, Vinh DC, Alsina L, Grumach A, Soler-Palacin P, Boyce T, Celmeli F, Goudouris E, Hayman G, Herriot R, Förster-Waldl E, Seidel M, Simons A, de Vries E. Primary immunodeficiency associated with chromosomal aberration - an ESID survey. Orphanet J Rare Dis 2016; 11:110. [PMID: 27484815 PMCID: PMC4971718 DOI: 10.1186/s13023-016-0492-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Accepted: 07/27/2016] [Indexed: 11/21/2022] Open
Abstract
Background Patients with syndromic features frequently suffer from recurrent respiratory infections, but little is known about the spectrum of immunological abnormalities associated with their underlying chromosomal aberrations outside the well-known examples of Down and DiGeorge syndromes. Therefore, we performed this retrospective, observational survey study. Methods All members of the European Society for Immunodeficiencies (ESID) were invited to participate by reporting their patients with chromosomal aberration (excluding Down and DiGeorge syndromes) in combination with one or more identified immunological abnormalities potentially relating to primary immunodeficiency. An online questionnaire was used to collect the patient data. Results Forty-six patients were included from 16 centers (24 males, 22 females; median age 10.4 years [range 1.0–69.2 years]; 36 pediatric, 10 adult patients). A variety of chromosomal aberrations associated with immunological abnormalities potentially relating to primary immune deficiency was reported. The most important clinical presentation prompting the immunological evaluation was ‘recurrent ear-nose-throat (ENT) and airway infections’. Immunoglobulin isotype and/or IgG-subclass deficiencies were the most prevalent immunological abnormalities reported. Conclusions Our survey yielded a wide variety of chromosomal aberrations associated with immunological abnormalities potentially relating to primary immunodeficiency. Although respiratory tract infections can often also be ascribed to other causes (e.g. aspiration or structural abnormalities), we show that a significant proportion of patients also have an antibody deficiency requiring specific treatment (e.g. immunoglobulin replacement, antibiotic prophylaxis). Therefore, it is important to perform immunological investigations in patients with chromosomal aberrations and recurrent ENT or airway infections, to identify potential immunodeficiency that can be specifically treated. Electronic supplementary material The online version of this article (doi:10.1186/s13023-016-0492-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ellen Schatorjé
- Department Pediatrics, Jeroen Bosch Hospital, P.O. Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands
| | - Michiel van der Flier
- Department of Pediatrics, Amalia Children's Hospital and Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
| | - Mikko Seppänen
- Immunodeficiency Unit, Inflammation Center and Center for Rare Diseases, Children's Hospital, Helsinki University and Helsinki University Hospital, Helsinki, Finland
| | | | | | - Stefanie Henriet
- Department of Pediatrics, Amalia Children's Hospital and Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands
| | - João Farela Neves
- Primary Immunodeficiencies unit Hospital Dona Estefania, Centro Hospitalar de Lisboa Central, Lisbon, Portugal
| | | | - Laia Alsina
- Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Barcelona, Spain
| | | | - Pere Soler-Palacin
- Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | | | - Fatih Celmeli
- Antalya Education and Research Hospital Department of Pediatric Immunology and Allergy, Antalya, Turkey
| | | | - Grant Hayman
- Epsom & St Helier University Hospitals NHS Trust, Carshalton, UK
| | | | - Elisabeth Förster-Waldl
- Department of Pediatrics and Adolescent Medicine, Center for Congenital Immunodeficiencies, Medical University Vienna, Wien, Austria
| | - Markus Seidel
- Pediatric Hematology-Oncology, Medical University Graz, Graz, Austria
| | - Annet Simons
- Department of Human Genetics, Radboudumc, Nijmegen, The Netherlands
| | - Esther de Vries
- Department Pediatrics, Jeroen Bosch Hospital, P.O. Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands. .,Department Tranzo, Tilburg University, Tilburg, The Netherlands.
| |
Collapse
|